Claims
- 1. A method for diagnosis of asthma including identifying a nucleic acid sequence exhibiting a polymorphism in an eotaxin gene, whereby that polymorphism comprises a substitution of adenine for guanine 67 base pairs following the ATG initiation codon of the gene, whereby counting is initiated at the A in that codon.
- 2. A method according to claim 1 including the step of identifying such polymorphism with respect to a normal wild type (normal) eotaxin gene (SEQ ID NO: 1).
- 3. A method according to claim 1, wherein the identifying step includes the steps of obtaining a biological sample from any of a patient, or relative thereof, and testing that sample to identify a polymorphism in nucleic acid contained therein or derived therefrom.
- 4. A method according to claim 3, wherein the identifying step includes any of sequencing and probing the nucleic acid.
- 5. A method according to claim 4, wherein the identifying step includes the step of amplifying a nucleic acid contained in the biological sample or derived therefrom.
- 6. A method according to claim 5, wherein the amplifying step includes the step of amplifying the nucleic acid by polymerase chain reaction (PCR).
- 7. A method according to claim 6, wherein the identifying step includes the step of testing the nucleic acid by a single-strand conformation polymorphism (SSCP) technique.
- 8. A method according to any of claims 6 and 7, including the step of contacting the nucleic acid with a primers including any of the sequences
- 9. A method according to claim 6, wherein the identifying step includes the step of testing the nucleic acid by an amplification refractory mutation system (ARMS) technique.
- 10. A method according to claim 9, wherein the testing step includes the step of contacting the nucleic acid with a primers including any of the sequences
- 11. A method according to claim 1, wherein the identifying step includes the steps of obtaining a biological sample from any of a patent, or relative thereof, and testing that sample to identify a variant protein therein associated with the polymorphism.
- 12. A method according to claim 11, comprising identifying a variant eotaxin protein in which threonine is substituted for alanine in the 23rd position.
- 13. A method according to claim 12, wherein the substitution is with respect to a wild type (normal) eotaxin protein associated with a wild type (normal) eotaxin gene (SEQ ID NO: 1).
- 14. A method according to claim 13, wherein the identifying step includes the step of contacting the biological samples with immunolabeling agents.
- 15. A method according to claim 14, wherein the identifying step includes the step of contacting the biological sample with antibodies raised against a nucleotide sequence expected to occur in the variant protein.
- 16. A method for treatment of asthma including the steps of
A. identifying a nucleic acid sequence exhibiting a polymorphism in an eotaxin gene, whereby that polymorphism comprises a substitution of adenine for guanine 67 base pairs following the ATG initiation codon of the gene, whereby counting is initiated at the A in that codon, and B. remediating the substitution by replacing the adenine for guanine 67 base pairs following the ATG initiation codon of the gene, whereby counting is initiated at the A in that codon.
- 17. A compound for use in any of diagnosing, predicting and treating asthma comprising a nucleic acid substantially similar to at least a portion of a wild type (normal) exotaxin gene sequence (SEQ ID NO: 1) in which adenine is substituted for guanine 67 base pairs following the ATG initiation codon of the wile type gene, whereby counting is initiated at the A in that codon, and wherein said portion includes at least the foregoing substitution.
- 18. A compound for use in any of diagnosing, predicting and treating asthma comprising a nucleic acid substantially similar to at least a portion of a protein associated with a wild type (normal) exotaxin gene sequence (SEQ ID NO: 1) in which threonine is substituted for alanine in the 23rd position, and wherein said portion includes at least the foregoing substitution.
- 19. A compound for use in polymerase chain reaction amplification of nucleic acid sequences, the compound comprising any of the oligonucleotides:
- 20. A method for any of diagnosis, prediction and treatment of an inflammatory condition, wherein the method includes the step of identifying a nucleic acid sequence exhibiting a polymorphism in an eotaxin gene, whereby that polymorphism comprises a substitution of adenine for guanine 67 base pairs following the ATG initiation codon of the gene, whereby counting is initiated at the A in that codon.
- 21. A method according to claim 20 including the step of identifying such polymorphism with respect to a normal wild type (normal) eotaxin gene (SEQ ID NO: 1).
- 22. A method according to claim 20, wherein the identifying step includes the steps of obtaining a biological sample from any of a patent, or relative thereof, and testing that sample to identify a polymorphism in nucleic acid contained therein or derived therefrom.
- 23. A method according to claim 22, wherein the identifying step includes any of sequencing and probing the nucleic acid.
- 24. A method according to claim 23, wherein the identifying step includes the step of amplifying a nucleic acid contained in the biological sample or derived therefrom.
- 25. A method according to claim 24, wherein the amplifying step includes the step of amplifying the nucleic acid by polymerase chain reaction (PCR).
- 26. A method according to claim 25, wherein the identifying step includes the step of testing the nucleic acid by a single-strand conformation polymorphism (SSCP) technique.
- 27. A method according to any of claims 25 and 26, including the step of contacting the nucleic acid with a primers including any of the sequences
- 28. A method according to claim 25, wherein the identifying step includes the step of testing the nucleic acid by an amplification refractory mutation system (ARMS) technique.
- 29. A method according to claim 28, wherein the testing step includes the step of contacting the nucleic acid with a primers including any of the sequences
- 30. A method according to claim 20, wherein the identifying step includes the steps of obtaining a biological sample from any of a patent, or relative thereof, and testing that sample to identify a variant protein therein associated with the polymorphism.
- 31. A method according to claim 30, comprising identifying a variant eotaxin protein in which threonine is substituted for alanine in the 23rd position.
- 32. A method according to claim 31, wherein the substitution is with respect to a wild type (normal) eotaxin protein associated with a wild type (normal) eotaxin gene (SEQ ID NO: 1).
- 33. A method according to claim 32, wherein the identifying step includes the step of contacting the biological samples with immunolabeling agents.
- 34. A method according to claim 33, wherein the identifying step includes the step of contacting the biological sample with antibodies raised against a nucleotide sequence expected to occur in the variant protein.
- 35. A method for treatment of an inflammatory condition including the steps of
A. identifying a nucleic acid sequence exhibiting a polymorphism in an eotaxin gene, whereby that polymorphism comprises a substitution of adenine for guanine 67 base pairs following the ATG initiation codon of the gene, whereby counting is initiated at the A in that codon, and B. remediating the substitution by replacing the adenine for guanine 67 base pairs following the ATG initiation codon of the gene, whereby counting is initiated at the A in that codon.
RELATED APPLICATIONS
[0001] This application claims priority under Title 35, United States Code, §119(e), of U. S. Provisional Application No. 60/046,720, filed May 16, 1997, and entitled “Methods for Diagnosis, Prediction and Treatment of Asthma and Other Inflammatory Conditions Based on Eotaxin Coding Sequence Polymorphism”, the entire contents of which are incorporated herein by reference.
SPONSORSHIP
[0002] This invention resulted from research sponsored, in part, by NIH Grant Number HL0328. The Government has certain rights in this invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60046720 |
May 1997 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09076259 |
May 1998 |
US |
Child |
10413255 |
Apr 2003 |
US |